secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001724521-25-000005
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Arcus appoints Richard Markus as CMO; Dimitry Nuyten departs Jan 31, 2025
-------------------------------------------------------------------------

- Richard Markus, M.D., Ph.D., named Chief Medical Officer, effective January 31, 2025.
- Dimitry Nuyten, M.D., Ph.D., will depart from Arcus on the same date.
- Dr. Nuyten eligible for lump-sum severance of 12 months base salary, 12 months COBRA, and 2024 bonus.
- Separation agreement details described; final agreement to be filed after execution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000005/0001724521-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000005/rcus-20250116.htm
  HTML page:      https://secwatch.observer/filing/0001724521-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer